Preserved High Probability of Overall Survival with Significant Reduction of Chemotherapy for Myeloid Leukemia in Down Syndrome: A Nationwide Prospective Study in Japan

Pediatric Blood and Cancer

Volumn 63, Issue 2, 2016, Pages 248-254

  Taga, Takashi ^a   Watanabe, Tomoyuki ^b   Tomizawa, Daisuke ^c   Kudo, Kazuko ^d   Terui, Kiminori ^e   Moritake, Hiroshi ^f   Kinoshita, Akitoshi ^g   Iwamoto, Shotaro ^h   Nakayama, Hideki ⁱ   Takahashi, Hiroyuki ^j   Shimada, Akira ^k   Taki, Tomohiko ^l   Toki, Tsutomu ^e   Ito, Etsuro ^e   Goto, Hiroaki ^m   Koh, Katsuyoshi ⁿ   Saito, Akiko M ^o   Horibe, Keizo ^o   Nakahata, Tatsutoshi ^p   Tawa, Akio ^q   Adachi, Souichi ^r   more..

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b AICHI GAKUIN UNIVERSITY   (Japan)

^c NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^d FUJITA HEALTH UNIVERSITY   (Japan)

^e HIROSAKI UNIVERSITY   (Japan)

^f UNIVERSITY OF MIYAZAKI   (Japan)

^g ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

ⁱ FUKUOKA HIGASHI MEDICAL CENTER   (Japan)

^j TOHO UNIVERSITY   (Japan)

^k OKAYAMA UNIVERSITY HOSPITAL   (Japan)

^l KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^m KANAGAWA CHILDREN'S MEDICAL CENTER   (Japan)

ⁿ SAITAMA CHILDREN'S MEDICAL CENTER   (Japan)

^o NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^p KYOTO UNIVERSITY   (Japan)

^q NATIONAL HOSPITAL ORGANIZATION   (Japan)

^r KYOTO UNIVERSITY   (Japan)

more..

Author keywords

acute myeloid leukemia; clinical trial; Down syndrome

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; CYTARABINE; ETOPOSIDE; PIRARUBICIN; VINCRISTINE;

ABSENCE OF SIDE EFFECTS; ACUTE MYELOBLASTIC LEUKEMIA; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CHILD; CONTINUOUS INFUSION; CONTROLLED STUDY; DOWN SYNDROME; DRUG DOSE INTENSIFICATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EVENT FREE SURVIVAL; FEMALE; HIGH RISK PATIENT; HUMAN; INDUCTION CHEMOTHERAPY; INFANT; JAPAN; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MALE; MOSAICISM; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; REFRACTORY ANEMIA WITH EXCESS BLASTS IN TRANSFORMATION; RISK FACTOR; SEPSIS; SIDE EFFECT; STANDARD; TREATMENT OUTCOME; TRISOMY 21;

EID: 85006320195     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.25789     Document Type: Article

References (17)

1. Creutzig U, Reinhardt D, Diekamp S, Dworzak M, Stary J, Zimmermann M. AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity. Leukemia 2005;19:1355–1360.
2. Abildgaard L, Ellebaek E, Gustafsson G, Abrahamsson J, Hovi L, Jonmundsson G, Zeller B, Hasle H. Optimal treatment intensity in children with Down syndrome and myeloid leukaemia: Data from 56 children treated on NOPHO-AML protocols and review of the literature. Ann Haematol 2006;85:275–280.
3. Rao A, Hills RK, Stiller C, Gibson BE, de Graaf SS, Hann IM, O'Marcaigh A, Wheatley K, Webb DK. Treatment for myeloid leukaemia of Down syndrome: Population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials. Br J Haematol 2006;132:576–583.
4. Gamis AS, Woods WG, Alonzo TA, Buxton A, Lange B, Barnard DR, Gold S, Smith FO. Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: A report from the Children's Cancer Group Study 2891. J Clin Oncol 2003;21:3415–3422.
5. Sorrell AD, Alonzo TA, Hilden JM, Gerbing RB, Loew TW, Hathaway L, Barnard D, Taub JW, Ravindranath Y, Smith FO, Arceci RJ, Woods WG, Gamis AS. Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced-dose chemotherapy on Children's Oncology Group trial A2971: A report from the Children's Oncology Group. Cancer 2012;118:4806–4814.
6. Kudo K, Kojima S, Tabuchi K, Yabe H, Tawa A, Imaizumi M, Hanada R, Hamamoto K, Kobayashi R, Morimoto A, Nakayama H, Tsuchida M, Horibe K, Kigasawa H, Tsukimoto I. Prospective study of a pirarubicin, intermediate-dose cytarabine, and etoposide regimen in children with Down syndrome and acute myeloid leukemia: The Japanese Childhood AML Cooperate Study Group. J Clin Oncol 2007;25:5442–5447.
7. Taga T, Shimomura Y, Horikoshi Y, Ogawa A, Itoh M, Okada M, Ueyama J, Higa T, Watanabe A, Kanegane H, Iwai A, Saiwakawa Y, Kogawa K, Yamanaka J, Tsurusawa M. Continuous and high-dose cytarabine combined chemotherapy in children with Down syndrome and acute myeloid leukemia: Report from the Japanese Children's Cancer and Leukemia Study Group (JCCLSG) AML 9805 Down Study. Pediatr Blood Cancer 2011;57:36–40.
8. Baumann I, Niemeyer CM, Brunning RD, Porwit A. Myeloid proliferations related to Down syndrome. In Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thile J, Vardiman JW. WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edition. Lyon: IARC; 2008: p. 142–144.
9. Hasle H, Abrahamsson J, Arola M, Karow A, O'Marcaigh A, Reinhardt D, Webb DK, van Wering E, Zeller B, Zwaan CM, Vyas P. Myeloid leukemia in children 4 years or older with Down syndrome often lacks GATA1 mutation and cytogenetics and risk of relapse are more akin to sporadic AML. Leukemia 2008;22:1428–1430.
10. Sato A, Imaizumi M, Koizumi Y, Obara Y, Nakai H, Noro T, Saito T, Saisho T, Yoshinari M, Cui Y, Suzuki H, Funato T, Iinuma K. Acute myelogenous leukaemia with t(8;21)translocation of normal cell origin in mosaic Down's syndrome with isochromsome 21q. Br J Haematol 1997;96:614–616.
11. Kawamura M, Kaku H, Taketani T, Taki T, Shimada A, Hayashi Y. Mutations of GATA1, FLT3, MLL-partial tandem duplication, NRAS, and RUNX1 genes are not found in a 7-year-old Down syndrome patient with acute myeloid leukemia (FAB-M2) having a good prognosis. Cancer Genet Cytoget 2008;180:74–78.
12. Blink M, Zimmermann M, von Neuhoff C, Reinhardt D, de Haas V, Hasle H, O'Brien MM, Stark B, Tandonnet J, Pession A, Tousovska K, Cheuk DK, Kudo K, Taga T, Rubnitz JE, Haltrich I, Balwierz W, Pieters R, Forestier E, Johansson B, van den Heuvel-Eibrink MM, Zwaan CM. Normal karyotype is a poor prognostic factor in myeloid leukemia of Down syndrome: A retrospective, international study. Haematologica 2014:299–307.
13. Al-Ahmari A, Shah N, Sung L, Zipursky A, Hitzler J. Long-term results of an ultra low-dose cytarabine-based regimen for the treatment of acute megakaryoblastic leukaemia in children with Down syndrome. Br J Haematol 2006;133:646–648.
14. Taga T, Saito AM, Kudo K, Tomizawa D, Terui K, Moritake H, Kinoshita A, Iwamoto S, Nakayama H, Takahashi H, Tawa A, Shimada A, Taki T, Kigasawa H, Koh K, Adachi S. Clinical characteristics and outcome of refractory/relapsed myeloid leukemia in children with Down syndrome. Blood 2012;120:1810–1815.
15. Caldwell JT, Edwards H, Buck SA, Ge Y, Taub JW. Targeting the wee1 kinase for treatment of pediatric Down syndrome acute myeloid leukemia. Pediatr Blood Cancer 2014;61:1767–1773.
16. Wen Q, Goldenson B, Silver SJ, Schenone M, Dancik V, Huang Z, Wang LZ, Lewis TA, An WF, Li X, Bray MA, Thiollier C, Diebold L, Gilles L, Vokes MS, Moore CB, Bliss-Moreau M, Verplank L, Tolliday NJ, Mishra R, Vemula S, Shi J, Wei L, Kapur R, Lopez CK, Gerby B, Ballerini P, Pflumio F, Gilliland DG, Goldberg L, Birger Y, Izraeli S, Gamis AS, Smith FO, Woods WG, Taub J, Scherer CA, Bradner JE, Goh BC, Mercher T, Carpenter AE, Gould RJ, Clemons PA, Carr SA, Root DE, Schreiber SL, Stern AM, Crispino JD. Identification of regulators of polyploidization presents therapeutic targets for treatment of AMKL. Cell 2012;150:575–589.
17. Stankov MV, El Khatib M, Kumar Thakur B, Heitmann K, Panayotova-Dimitrova D, Schoening J, Bourquin JP, Schweitzer N, Leverkus M, Welte K, Reinhardt D, Li Z, Orkin SH, Behrens GM, Klusmann JH. Histone deacetylase inhibitors induce apoptosis in myeloid leukemia by suppressing autophagy. Leukemia 2014;28:577–588.